RYZB NASDAQ
RayzeBio, Inc. Common Stock
1W: +0.0%
1M: +0.6%
3M: +143.2%
$62.49
Last traded 2024-03-06 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$72M
-83.1% ▼
Net Income
-$69M
-133.0% ▼
EPS (Diluted)
$-1.75
-139.7% ▼
EBITDA
-$71M
-81.4% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Gross Margin | — | — | — |
| R&D Expenses | $6M | $34M | $61M |
| SG&A Expenses | $1M | $6M | $11M |
| Operating Expenses | $7M | $39M | $72M |
| Operating Income | -$7M | -$39M | -$72M |
| Operating Margin | — | — | — |
| Interest Expense | $0 | $0 | $0 |
| Income Before Tax | -$7M | -$29M | -$69M |
| Tax Expense | $0 | $0 | $0 |
| Net Income | -$7M | -$29M | -$69M |
| Net Margin | — | — | — |
| EPS (Diluted) | $-0.17 | $-0.73 | $-1.75 |
| EBITDA | -$7M | -$39M | -$71M |
| Shares Outstanding | 40M | 40M | 39M |